SELLAS Life Sciences Group (NASDAQ:SLS) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw an uptick in trading volume on Tuesday . Approximately 6,253,825 shares changed hands during trading, a decline of 25% from the previous session’s volume of 8,341,135 shares.The stock last traded at $14.1320 and had previously closed at $15.45.

Analysts Set New Price Targets

Several equities analysts have weighed in on SLS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group increased their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Trading Down 5.2%

The company has a 50 day simple moving average of $7.35 and a two-hundred day simple moving average of $5.27. The firm has a market capitalization of $2.88 billion, a P/E ratio of -63.43 and a beta of 2.50.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of hedge funds have recently made changes to their positions in the company. Dagco Inc. bought a new stake in SELLAS Life Sciences Group in the 4th quarter worth approximately $2,177,000. Anson Funds Management LP grew its holdings in shares of SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after purchasing an additional 5,757,938 shares in the last quarter. Everhart Financial Group Inc. increased its position in SELLAS Life Sciences Group by 40.8% in the fourth quarter. Everhart Financial Group Inc. now owns 466,216 shares of the company’s stock worth $1,758,000 after purchasing an additional 135,066 shares during the last quarter. World Investment Advisors purchased a new stake in SELLAS Life Sciences Group during the fourth quarter valued at $166,000. Finally, Trustmark Bank Trust Department bought a new position in SELLAS Life Sciences Group during the third quarter valued at $59,000. 17.38% of the stock is currently owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.